澳大利亚企业在采矿和生物技术部门取得进展,但Opthea面临偿付能力问题。 Australian firms advance in mining and biotech sectors, but Opthea faces solvency issues.

澳大利亚公司正在采矿和生物技术方面进行移动。 Australian companies are making moves in mining and biotech. 分辨率矿物公司收购了富含、金和铜的项目,而Terra金属公司则显示出具有高等级矿物精矿的潜力。 Resolution Minerals acquired projects rich in antimony, gold, and copper, while Terra Metals showed potential for high-grade mineral concentrates. 在生物技术方面,先锋疗法师任命Marissa Lim博士为首席医疗官,加强了癌症治疗工作。 In biotech, Prescient Therapeutics appointed Dr. Marissa Lim as Chief Medical Officer, enhancing its cancer therapy efforts. 同时,Opthea有限公司在一次关键审判失败后面临偿付能力问题。 Meanwhile, Opthea Limited faces solvency concerns after a key trial failure. 在受利率和关税发展影响下, ASX 200上星期上升1.82%, 但预计下一期会下降。 The ASX 200 saw a 1.82% rise last week but is expected to decline in the coming session, influenced by interest rates and tariff developments.